Key facts
- It has raised $53.4M; the latest was Early Stage VC ($2.1M) in Nov 2024.
- Notable investors include SoftBank Investment Advisers, The Engine, iAngels, GlenRock Israel, First Avenue Ventures — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Quris AI
- ·The full record, as it builds
Funding rounds
No funding rounds for Quris AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Quris AI
Developer of an artificial intelligence-powered bio clinical-prediction platform designed to ensure the safety and efficacy of new drugs. The company's platform is fully automated and self-trained and predicts clinical safety and efficacy for novel drugs faster and cost-effectively while minimizing animal testing using patients-on-a-chip technology, enabling pharma companies to avoid the tremendous risks and costs of failed clinical trials and end the reliance on ineffective animal testing.
- Sector
- Healthcare
- HQ
- Tel Aviv, Israel
- Founded
- 2020
- Employees
- 47
- Website
- quris.ai/
- Ownership
- Privately Held (backing)
Quris AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Quris AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Quris AI in its N-PORT filings yet. We sweep new filings monthly.